On January 22nd, a paper titled “Intravesical Instillation of Chemotherapy Before Radical Surgery for Upper Urinary Tract Urothelial Carcinoma: The REBACARE Trial” was published in European Urology Journal by Thomas van Doeveren et al.
Authors: Thomas van Doeveren, Sebastiaan Remmers, Egbert Boevé, Pim van Leeuwen, Joost Boormans et al.
The REBACARE Trial investigated a novel approach to reducing intravesical recurrence (IVR) in upper urinary tract urothelial carcinoma (UTUC) patients.
This prospective, multi-institutional phase 2 clinical trial examined preoperative intravesical chemotherapy (IIC) for upper urinary tract urothelial carcinoma (UTUC) in 190 chemonaive patients. The study involved 190 chemonaive patients receiving a single mitomycin C instillation before surgery.
The 2-year intravesical recurrence (IVR) rate was 24%, with patients without diagnostic ureteroscopy (d-URS) showing a threefold lower recurrence risk. Compliance was high at 96%, and no significant toxicity was observed.
Preoperative IIC demonstrated effectiveness in reducing IVR risk, particularly for patients without prior diagnostic ureteroscopy. The research suggests this approach as a viable strategy for UTUC management, recommending judicious use of diagnostic ureteroscopy.
Read the post “Immunotherapy for Bladder Cancer: Types, Success Rate, Side Effects & More” on oncodaily.com.
